US Bancorp
RYTM icon

US Bancorp’s Rhythm Pharmaceuticals RYTM Stock Holding History

US Bancorp’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.5K Buy
1,041
+88
+9% +$8.56K ﹤0.01% 2436
2025
Q4 		$102K Buy
953
+807
+553% +$85.6K ﹤0.01% 2356
2025
Q3 		$14.7K Hold
146
– – ﹤0.01% 3189
2025
Q2 		$9.23K Hold
146
– – ﹤0.01% 3458
2025
Q1 		$7.73K Buy
146
+5
+4% +$277 ﹤0.01% 3521
2024
Q4 		$7.89K Hold
141
– – ﹤0.01% 3504
2024
Q3 		$7.39K Hold
141
– – ﹤0.01% 3459
2024
Q2 		$5.79K Buy
141
+79
+127% +$3.15K ﹤0.01% 3471
2024
Q1 		$2.69K Hold
62
– – ﹤0.01% 3666
2023
Q4 		$2.85K Sell
62
-48
-44% -$1.51K ﹤0.01% 3647
2023
Q3 		$2.52K Sell
110
-953
-90% -$21.3K ﹤0.01% 3602
2023
Q2 		$17.5K Buy
1,063
+1,018
+2,262% +$18.4K ﹤0.01% 3039
2023
Q1 		$803 Hold
45
– – ﹤0.01% 3901
2022
Q4 		$1.31K Hold
45
– – ﹤0.01% 3879
2022
Q3 		$1K Buy
+45
New +$837 ﹤0.01% 4001
2022
Q2 		– Sell
-130
Closed -$1K – 4205
2022
Q1 		$1K Sell
130
-3,034
-96% -$26.6K ﹤0.01% 3989
2021
Q4 		$32K Buy
3,164
+3,068
+3,196% +$34.5K ﹤0.01% 2875
2021
Q3 		$1K Sell
96
-40
-29% -$611 ﹤0.01% 4011
2021
Q2 		$3K Sell
136
-358
-72% -$7.43K ﹤0.01% 3759
2021
Q1 		$11K Sell
494
-335
-40% -$9.72K ﹤0.01% 3251
2020
Q4 		$25K Buy
829
+368
+80% +$9.35K ﹤0.01% 2823
2020
Q3 		$10K Buy
461
+356
+339% +$8.16K ﹤0.01% 3086
2020
Q2 		$2K Buy
+105
New +$2.05K ﹤0.01% 3529
2019
Q2 		– Sell
-99
Closed -$3K – 3661
2019
Q1 		$3K Buy
+99
New +$2.85K ﹤0.01% 3362

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

US Bancorp's RYTM Position: Q1 2026 in Review

US Bancorp increased its Rhythm Pharmaceuticals (RYTM) stake by 9.2% in Q1 2026, buying an estimated $8.56K and bringing the position to 1,041 shares worth $90.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

US Bancorp first reported a position in RYTM in Q1 2019 and has held it in 24 quarters since. The position peaked at $102K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • US Bancorp held 1,041 shares of Rhythm Pharmaceuticals worth $90.5K as of Q1 2026.
  • US Bancorp bought 88 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $8.56K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #2436 holding.
  • US Bancorp first reported a position in Rhythm Pharmaceuticals in Q1 2019 and has held it in 24 quarters since.
  • US Bancorp's Rhythm Pharmaceuticals position peaked at $102K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.